300+ investors in your industry, stage, and region Get
Any industry
Google
Clean Energy
EdTech
Artificial Intelligence
Local
Enterprise Software
Travel
Platforms
Oil and Gas
InsurTech
Retail
Social Impact
Cryptocurrency
SaaS
Film
Photography
Restaurants
Email
CleanTech
Payments
Energy
Marketplace
Fitness
Organic Food
Machine Learning
Health Care
Agriculture (AgTech)
Gaming
Social Network
Facebook
Blockchain
B2B
Video Games
Big Data
Medical Device
Wellness
Education
Mobile
Automotive
Sports
Legal
eSports
Construction
Hospitality
Biotechnology
Consumer
Software
Renewable Energy
Crowdfunding
Theatre
Medical
Recruiting
Web3
Venture Capital
Fashion
Social
Beauty
Infrastructure
Cannabis
LGBT
Celebrity
Climate
Mobile Apps
Life Science
Wine and Spirits
Food and Beverage
Publishing
Music
Art
Real Estate
Sporting Goods
Manufacturing
Digital Media
FinTech
Finance
Financial Services
Social Media
Franchise
Mobile Advertising
Non Profit
Internet
Android
Sustainability
Hardware
Biotech
Impact
Proptech
Transportation
Enterprise
Community
Media (Entertainment)
Any country
Hong Kong
Thailand
United Arab Emirates
Egypt
Croatia
Burkina Faso
South Korea
Singapore
Brazil
Kyrgyzstan
LATAM
Africa
Oceania
Gibraltar
Liberia
Taiwan
Tunisia
Sweden
Zimbabwe
Zambia
Norway
Tajikistan
Mexico
Nigeria
Russian Federation
Togo
Guinea
Nepal
Iran
Isle of Man
Madagascar
Pakistan
Romania
Greece
Oman
Puerto Rico
Poland
Cameroon
Guernsey
Andorra
Colombia
Sudan
China
Armenia
Costa Rica
Czech Republic
Kenya
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
New Zealand
Morocco
Australia
Saudi Arabia
Sri Lanka
Jamaica
Switzerland
Guatemala
Kazakhstan
Cayman Islands
Venezuela
Malawi
Myanmar
Uganda
Turkey
Uruguay
Moldova
Botswana
Seychelles
Paraguay
Ireland
Japan
South Africa
France
Georgia
Denmark
Ghana
Iraq
Mali
Latvia
Malaysia
Portugal
Philippines
Sierra Leone
Rwanda
El Salvador
Senegal
Tanzania
Germany
India
United States
Indonesia
Middle East
Dominican Republic
Bermuda
Asia
Canada
Albania
Spain
Angola
Europe
Cyprus
Qatar
Argentina
Bangladesh
Belgium
Barbados
Jordan
Austria
Ethiopia
Azerbaijan
Bulgaria
Ecuador
Bahamas
Faroe Islands
Estonia
Jersey
Bahrain
Bolivia
Algeria
Belize
Finland
Italy
Belarus
Hungary
Grenada
Israel
Iceland
Cambodia
Honduras
Lithuania
Liechtenstein
Lebanon
Mongolia
United Kingdom
Peru
Slovenia
San Marino
Ukraine
Vietnam
Chile
Angel Investors
VC Funds
All Investors
Access Full Database - Free Forever
Open database
Ian Warwick, Director at Liverpool ChiroChem

Ian Warwick

Director @ Liverpool ChiroChem

Ian Warwick is a Series A investor at Liverpool ChiroChem focused on Mobile and Medical. Ian Warwick is the Managing Partner at Deepbridge Capital LLP.

Total investments:
8
Last investment:
Lead investor:
50%

Last updated:

Industries Ian Warwick invests in

MobileMedicalConsumerSoftwareMessaging

Stages Ian Warwick invests in

Series AFunding RoundSeedSeries BPrivate Equity

Countries Ian Warwick invests in

United Kingdom

Investment Focus

Industry

  • Mobile 1 (13%)
  • Medical 1 (13%)
  • Consumer 1 (13%)
  • Software 1 (13%)
  • Messaging 1 (13%)
See all 14 industries →

Stage

  • Series A 3 (38%)
  • Funding Round 2 (25%)
  • Seed 1 (13%)
  • Series B 1 (13%)
  • Private Equity 1 (13%)

Investments

CompanyDescriptionRoundLinks
VoxSmart VoxSmart
VoxSmart is a global communications surveillance software provider headquartered in London, UK with offices in Madrid, Singapore and New York. VoxSmart helps businesses see their communications data in a clear and compliant way to effectively mitigate business risks by delivering critical insights and business intelligence in near real-time.VoxSmart designs, develops, and deploys capture and surveillance solutions that collect all communications sources from phone calls, emails, mobiles right through to WhatsApp into one single monitoring platform. The company's multi-award winning solution, VoxSmart Mobile Capture, empowers organisations to unlock the power of mobility whilst achieving regulatory and internal compliance by recording all mobile communications on any network, anywhere in the world. Mobile Capture is fully compliant and adheres to global regulation, is Cloud based and is deployed remotely with no interference to your user experience.Through recent M&A activity, VoxSmart now provides market leading voice and electronic Communications Surveillance and Automatic Trade Reconstruction technology that helps firms monitor employ conduct and trading activity in an efficient and cost-effective way, while ensuring records can be accurately reconciled within very short time-frames to adhere to global regulation. We pride ourselves in offering the Financial Services the most comprehensive suite of surveillance products that addresses key challenges around data integration, processing and analytics. $25M / Mar 22, 2021
VoxSmart VoxSmart
VoxSmart is a global communications surveillance software provider headquartered in London, UK with offices in Madrid, Singapore and New York. VoxSmart helps businesses see their communications data in a clear and compliant way to effectively mitigate business risks by delivering critical insights and business intelligence in near real-time.VoxSmart designs, develops, and deploys capture and surveillance solutions that collect all communications sources from phone calls, emails, mobiles right through to WhatsApp into one single monitoring platform. The company's multi-award winning solution, VoxSmart Mobile Capture, empowers organisations to unlock the power of mobility whilst achieving regulatory and internal compliance by recording all mobile communications on any network, anywhere in the world. Mobile Capture is fully compliant and adheres to global regulation, is Cloud based and is deployed remotely with no interference to your user experience.Through recent M&A activity, VoxSmart now provides market leading voice and electronic Communications Surveillance and Automatic Trade Reconstruction technology that helps firms monitor employ conduct and trading activity in an efficient and cost-effective way, while ensuring records can be accurately reconciled within very short time-frames to adhere to global regulation. We pride ourselves in offering the Financial Services the most comprehensive suite of surveillance products that addresses key challenges around data integration, processing and analytics. $25M / Private Equity / Mar 22, 2021
Touch Biometrix Touch Biometrix
Touch Biometrix is a company founded in 2017 with the express purpose of developing a revolutionary new fingerprint authentication platform. This will be based on new sensing technology coupled with a new manufacturing model that will deliver high performance fingerprint sensors of any shape or size and at market leading cost points. TouchBiometrix aim to make smart objects even smarter with a new paradigm in user friendly identity authentication.​ $2.6M / Series A / Apr 18, 2019
Touch Biometrix Touch Biometrix
Touch Biometrix is a company founded in 2017 with the express purpose of developing a revolutionary new fingerprint authentication platform. This will be based on new sensing technology coupled with a new manufacturing model that will deliver high performance fingerprint sensors of any shape or size and at market leading cost points. TouchBiometrix aim to make smart objects even smarter with a new paradigm in user friendly identity authentication.​ $196K / Seed / May 09, 2018
Sky Medical Technology Sky Medical Technology
Sky Medical Technology is a growth-stage bioelectronic medicine platform that completely redefines the way vascular related conditions are treated. The company has developed a neuromodulation therapy called OnPulse™, the first clinically proven bioelectronic compression technology to prevent and treat a wide range of acute and chronic circulatoryconditions. The first indications for the OnPulse wearable therapy are life threatening blood clots, swelling after orthopedic surgery, long term non-healing wounds, as well as applications for pro athletes to speed-up recovery time between games and during travel, conditions experienced by more than forty million people currently with unmet need. $13.5M / Series B / Sep 01, 2017
VoxSmart VoxSmart
VoxSmart is a global communications surveillance software provider headquartered in London, UK with offices in Madrid, Singapore and New York. VoxSmart helps businesses see their communications data in a clear and compliant way to effectively mitigate business risks by delivering critical insights and business intelligence in near real-time.VoxSmart designs, develops, and deploys capture and surveillance solutions that collect all communications sources from phone calls, emails, mobiles right through to WhatsApp into one single monitoring platform. The company's multi-award winning solution, VoxSmart Mobile Capture, empowers organisations to unlock the power of mobility whilst achieving regulatory and internal compliance by recording all mobile communications on any network, anywhere in the world. Mobile Capture is fully compliant and adheres to global regulation, is Cloud based and is deployed remotely with no interference to your user experience.Through recent M&A activity, VoxSmart now provides market leading voice and electronic Communications Surveillance and Automatic Trade Reconstruction technology that helps firms monitor employ conduct and trading activity in an efficient and cost-effective way, while ensuring records can be accurately reconciled within very short time-frames to adhere to global regulation. We pride ourselves in offering the Financial Services the most comprehensive suite of surveillance products that addresses key challenges around data integration, processing and analytics. $7M / Series A / Feb 07, 2017
Sky Medical Technology Sky Medical Technology
Sky Medical Technology is a growth-stage bioelectronic medicine platform that completely redefines the way vascular related conditions are treated. The company has developed a neuromodulation therapy called OnPulse™, the first clinically proven bioelectronic compression technology to prevent and treat a wide range of acute and chronic circulatoryconditions. The first indications for the OnPulse wearable therapy are life threatening blood clots, swelling after orthopedic surgery, long term non-healing wounds, as well as applications for pro athletes to speed-up recovery time between games and during travel, conditions experienced by more than forty million people currently with unmet need. $15M / Series A / Feb 01, 2015
Sky Medical Technology Sky Medical Technology
Sky Medical Technology is a growth-stage bioelectronic medicine platform that completely redefines the way vascular related conditions are treated. The company has developed a neuromodulation therapy called OnPulse™, the first clinically proven bioelectronic compression technology to prevent and treat a wide range of acute and chronic circulatoryconditions. The first indications for the OnPulse wearable therapy are life threatening blood clots, swelling after orthopedic surgery, long term non-healing wounds, as well as applications for pro athletes to speed-up recovery time between games and during travel, conditions experienced by more than forty million people currently with unmet need. Jan 01, 2013

Co-Investors

Juno Capital Partners Juno Capital Partners 3 deals together
Toscafund Asset Management Toscafund Asset Management 2 deals together
ACF Investors ACF Investors 1 deal together
Longbow Capital Longbow Capital 1 deal together
Liverpool ChiroChem

About Liverpool ChiroChem

VC Fund · Liverpool, United Kingdom

Liverpool ChiroChem (LCC) is a chemistry-based CRO that produces chiral small molecules for biotech/pharmaceutical R&D. Their specialist products can be used as building blocks, fragments and screening compounds to enable small molecule drug discovery. their chemical technologies provide efficient access to novel chiral building blocks forhit identification and hit-to-lead optimization.LCC’s catalytic methods give access to a wide range of chiral amines in excellent enantiomeric purity. Their initial focus is on the production and supply of chiral piperidines and other sp3-rich nitrogen heterocycles , which are of great importance to drug discovery and development due to their excellent pharmacokinetic properties e.g. improved solubility and bioavailability. LCC's technologies were developed through years of research in the areas of asymmetric hydrogenation and Pd-coupling. LCC now provide collaborate services with their customers to optimise key steps in synthetic routes.

Liverpool ChiroChem Contacts

NameEmailPhoneSocials
Ian Warwick
Ian Warwick Director
Jiwu Ruan
Jiwu Ruan Co-founder and CSO
Paul Colbon
Paul Colbon Co-founder & CEO
Philip Tottey
Philip Tottey CFO
Samuel Kirkwood
Samuel Kirkwood Business Development Manager

Sign up to unlock verified contacts

Unlock Contacts

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Find investors for your startup

Search 48,091 investors by industry and country. Emails and phones included.

Any industry
Google
Clean Energy
EdTech
Artificial Intelligence
Local
Enterprise Software
Travel
Platforms
Oil and Gas
InsurTech
Retail
Social Impact
Cryptocurrency
SaaS
Film
Photography
Restaurants
Email
CleanTech
Payments
Energy
Marketplace
Fitness
Organic Food
Machine Learning
Health Care
Agriculture (AgTech)
Gaming
Social Network
Facebook
Blockchain
B2B
Video Games
Big Data
Medical Device
Wellness
Education
Mobile
Automotive
Sports
Legal
eSports
Construction
Hospitality
Biotechnology
Consumer
Software
Renewable Energy
Crowdfunding
Theatre
Medical
Recruiting
Web3
Venture Capital
Fashion
Social
Beauty
Infrastructure
Cannabis
LGBT
Celebrity
Climate
Mobile Apps
Life Science
Wine and Spirits
Food and Beverage
Publishing
Music
Art
Real Estate
Sporting Goods
Manufacturing
Digital Media
FinTech
Finance
Financial Services
Social Media
Franchise
Mobile Advertising
Non Profit
Internet
Android
Sustainability
Hardware
Biotech
Impact
Proptech
Transportation
Enterprise
Community
Media (Entertainment)
Any country
Hong Kong
Thailand
United Arab Emirates
Egypt
Croatia
Burkina Faso
South Korea
Singapore
Brazil
Kyrgyzstan
LATAM
Africa
Oceania
Gibraltar
Liberia
Taiwan
Tunisia
Sweden
Zimbabwe
Zambia
Norway
Tajikistan
Mexico
Nigeria
Russian Federation
Togo
Guinea
Nepal
Iran
Isle of Man
Madagascar
Pakistan
Romania
Greece
Oman
Puerto Rico
Poland
Cameroon
Guernsey
Andorra
Colombia
Sudan
China
Armenia
Costa Rica
Czech Republic
Kenya
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
New Zealand
Morocco
Australia
Saudi Arabia
Sri Lanka
Jamaica
Switzerland
Guatemala
Kazakhstan
Cayman Islands
Venezuela
Malawi
Myanmar
Uganda
Turkey
Uruguay
Moldova
Botswana
Seychelles
Paraguay
Ireland
Japan
South Africa
France
Georgia
Denmark
Ghana
Iraq
Mali
Latvia
Malaysia
Portugal
Philippines
Sierra Leone
Rwanda
El Salvador
Senegal
Tanzania
Germany
India
United States
Indonesia
Middle East
Dominican Republic
Bermuda
Asia
Canada
Albania
Spain
Angola
Europe
Cyprus
Qatar
Argentina
Bangladesh
Belgium
Barbados
Jordan
Austria
Ethiopia
Azerbaijan
Bulgaria
Ecuador
Bahamas
Faroe Islands
Estonia
Jersey
Bahrain
Bolivia
Algeria
Belize
Finland
Italy
Belarus
Hungary
Grenada
Israel
Iceland
Cambodia
Honduras
Lithuania
Liechtenstein
Lebanon
Mongolia
United Kingdom
Peru
Slovenia
San Marino
Ukraine
Vietnam
Chile
Angel Investors
VC Funds
All Investors

Similar Investors

Recommended lists

FAQ

What does Ian Warwick invest in?

Ian Warwick invests primarily in Mobile, Medical and Consumer startups, most often at Series A and Funding Round stage. Most of the 8 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.

When did Ian Warwick last invest?

The most recent investment recorded for Ian Warwick closed in Mar 2021. Shizune tracks 8 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

Contact your first 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!
Ian Warwick Ian Warwick Find email